|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM030921155 |
| 003 |
DE-627 |
| 005 |
20231221115221.0 |
| 007 |
tu |
| 008 |
231221s1987 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0103.xml
|
| 035 |
|
|
|a (DE-627)NLM030921155
|
| 035 |
|
|
|a (NLM)3110794
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Martin, A J
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine
|
| 264 |
|
1 |
|c 1987
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 11.08.1987
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A total of 6258 patients seen in general practice complaining of low mood with or without associated somatic symptoms was studied. The mean patient entry score on the Montgomery-Asberg Depression Rating Scale (MADRS) was 29.69 (moderately severe depressive disorder). Three-quarters (73%) of the patients were female, average age was 46.1 years, and a reactive element was considered to be present in 43%. Patients received fluvoxamine, a novel anti-depressant, over a treatment period of 6 weeks, dosage starting at either 50 or 100 mg at night increasing after the first week, if necessary, to a maximum of 300 mg per day. Results were analyzed for 5625 patients. Efficacy of treatment was assessed using the MADRS, Psychosomatic Symptom Scale and Clinical Global Impression scales. During treatment, there was a marked improvement in mood and a parallel improvement in somatic symptoms; there was no difference in overall response between those with or without somatic symptoms. By Week 6, patients had improved by approximately 65%, with suicidal ideation being most marked at 81%. Patient compliance was good, the most commonly reported unwanted effect being nausea. In overdoses up to 2 g fluvoxamine no lasting toxic effects were observed. In an 'elderly' sub-group of 1096 patients aged 60 years and over, efficacy and the incidence of unwanted effects were similar, but the drop-out rate due to intolerance was greater than in the younger age sub-group
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antidepressive Agents
|2 NLM
|
| 650 |
|
7 |
|a Oximes
|2 NLM
|
| 650 |
|
7 |
|a Fluvoxamine
|2 NLM
|
| 650 |
|
7 |
|a O4L1XPO44W
|2 NLM
|
| 700 |
1 |
|
|a Tebbs, V M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ashford, J J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 5(1987), 1 vom: 10., Seite 40-9
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:5
|g year:1987
|g number:1
|g day:10
|g pages:40-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 5
|j 1987
|e 1
|b 10
|h 40-9
|